Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): Two randomised double-blind, placebo-controlled phase 3 trials

The Lancet Respiratory Medicine

Volumn 2, Issue 9, 2014, Pages 738-749

  Barker, Alan F ^a   O'Donnell, Anne E ^b   Flume, Patrick ^c   Thompson, Philip J ^d   Ruzi, Jonathan D ^e   De Gracia, Javier ^f   Boersma, Wim G ^g   De Soyza, Anthony ^h   Shao, Lixin ⁱ   Zhang, Jenny ⁱ   Haas, Laura ⁱ   Lewis, Sandra A ⁱ   Leitzinger, Sheila ⁱ   Montgomery, A Bruce ^j   McKevitt, Matthew T ⁱ   Gossage, David ⁱ   Quittner, Alexandra L ^k   O'Riordan, Thomas G ⁱ  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e Virginia G Piper Cancer Center   (United States)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g Location Alkmaar   (Netherlands)

^h NEWCASTLE UNIVERSITY   (United Kingdom)

ⁱ GILEAD SCIENCES   (United States)

^j Cardeas Pharma   (United States)

^k UNIVERSITY OF MIAMI   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; ANTIINFECTIVE AGENT;

ACHROMOBACTER; ADULT; AGED; ANAMNESIS; ARTICLE; BACTERIUM CULTURE; BRONCHIECTASIS; BURKHOLDERIA; CHILL; CITROBACTER; COLONY FORMING UNIT; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENTEROBACTER; ESCHERICHIA; FATIGUE; FEMALE; FEVER; GRAM NEGATIVE BACTERIUM; HEADACHE; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; MALAISE; MALE; MORAXELLA; NON CYSTIC FIBROSIS BRONCHIECTASIS; NONCARDIAC CHEST PAIN; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL; PROTEUS; PSEUDOMONAS; QUALITY OF LIFE; QUALITY OF LIFE BRONCHIECTASIS RESPIRATORY SYMPTOMS SCORE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SERRATIA; SPUTUM; SPUTUM ANALYSIS; SPUTUM DISCOLORATION; STENOTROPHOMONAS; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT CONGESTION; VERY ELDERLY; WHEEZING; YOUNG ADULT; ADOLESCENT; CHEMICALLY INDUCED; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; TIME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZTREONAM; BRONCHIECTASIS; COUGH; DOUBLE-BLIND METHOD; DYSPNEA; FEMALE; GRAM-NEGATIVE BACTERIA; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SPUTUM; TIME; YOUNG ADULT;

EID: 84908070796     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70165-1     Document Type: Article

References (28)

1. Barker AF Bronchiectasis. N Engl J Med 2002, 346:1383-1393.
2. O'Donnell AE Bronchiectasis. Chest 2008, 134:815-823.
3. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007, 101:1633-1638.
4. Döring G, Flume P, Heijerman H, Elborn JS Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012, 11:461-479. Consensus Study Group.
5. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000, 162:481-485.
6. Evans DJ, Bara AI, Greenstone M Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev 2007, 2. CD001392.
7. Drobnic ME, Suñé P, Montoro JB, Ferrer A, Orriols R Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005, 39:39-44.
8. Scheinberg P, Shore E A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005, 127:1420-1426.
9. Bilton D, Henig N, Morrissey B, Gotfried M Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006, 130:1503-1510.
10. Steinfort DP, Steinfort C Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J 2007, 37:495-498.
11. Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011, 183:491-499.
12. Serisier DJ, Bowler SD Randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. . .without patient blinding. Am J Respir Crit Care Med 2012, 186:461.
13. Haworth C, Foweraker J, Wilkinson P, Kenyon R, Bilton D Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014, 189:975-982.
14. Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013, 68:812-817.
15. Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013, 41:1107-1115.
16. Smith MP, Hill AT Evaluating success of therapy for bronchiectasis: what end points to use?. Clin Chest Med 2012, 33:329-349.
17. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008, 178:921-928.
18. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 2009, 135:1223-1232.
19. Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010, 45:1121-1134.
20. Quittner AL, Marciel KK, Salathe MA, et al. A preliminary Quality of Life Questionnaire-Bronchiectasis: A patient-reported outcome measure for bronchiectasis. Chest 2014, E-pub ahead of print.
21. Olveira C, Olveira G, Espildora F, et al. Validation of a quality of life questionnaire for bronchiectasis: psychometric analyses of the Spanish QOL-B-V3.0. Qual Life Res 2014, 23:1279-1292.
22. O'Donnell AE, Barker AF, Ilowite JS, Fick RB Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998, 113:1329-1334.
23. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012, 380:660-667.
24. Kanoh S, Rubin BK Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010, 23:590-615.
25. Tarran R, Sabater JR, Clarke TC, et al. Nonantibiotic macrolides prevent human neutrophil elastase-induced mucus stasis and airway surface liquid volume depletion. Am J Physiol Lung Cell Mol Physiol 2013, 304:L746-L756.
26. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013, 309:1251-1259.
27. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013, 309:1260-1267.
28. Chalmers JD, Goeminne P, Aliberti S, et al. The Bronchiectasis Severity Index: an international derivation and validation study. Am J Respir Crit Care Med 2014, 89:576-585.